SeattleNTC is expanding its options for treatment resistant depression to include the newly FDA-approved Spravato (esketamine nasal spray).
Esketamine is a promising new antidepressant that has the potential to work quickly – unlike with traditional oral antidepressants, many patients feel better after the first or second treatment. Esketamine, also known by the brand name Spravato, is chemically related to ketamine, and is administered as a nasal spray. Esketamine works in approximately 5 out of every 10 patients with treatment-resistant depression.
Esketamine is administered two times per week for four weeks and, if effective, is then administered once per week afterwards. Per FDA regulations, patients taking esketamine self-administer the medication in a physician’s office and must be monitored in the office for 2 hours. We offer esketamine treatments at our Bellevue location.